(HealthDay News) — In patients co-infected with HIV and hepatitis C virus (HCV), eradication of HCV is associated with a reduction in the risk of diabetes mellitus, according to a study published online in Hepatology.
Juan Berenguer, MD, PhD, from the Hospital General Universitario Gregorio Marañón in Madrid, and colleagues assessed non-liver-related, non-AIDS-related (NLR-NAR) events and mortality in a cohort of HIV/HCV-co-infected patients who were treated with interferon and ribavirin. The authors examined the hazard ratio of overall death for responders and non-responders after adjustment for confounding variables, and assessed the adjusted sub-hazard ratio (sHR) of NLR deaths and NLR-NAR events, with death as a competing risk.
The researchers found that 36% of the 1625 patients included had a sustained viral response (SVR). SVR correlated with a significant reduction in the risk of diabetes mellitus after a median 5-year follow-up (sHR, 0.57; 95% confidence interval, 0.35 to 0.93; P =.024) and a non-statistically significant reduction in the risk of chronic renal failure (sHR, 0.43; 95% confidence interval, 0.17 to 1.09; P =.075).
“Our data suggest that eradication of HCV in co-infected patients is associated not only with a reduction in the frequency of death, HIV progression, and liver-related events, but also with a reduced hazard of diabetes mellitus and possibly of chronic renal failure,” the authors write.
- Berenguer J, Rodríguez-Castellano E, Carrero A, et al. Eradication of HCV and non–liver-related non–AIDS-related events in HIV/HCV coinfection. Hepatology. 21 January 2017. doi: 10.1002/hep.29071. [Epub ahead of print]